We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+8.06%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$1.11T
AUM Growth
+$49.3B
Cap. Flow
-$2.91B
Cap. Flow %
-0.26%
Top 10 Hldgs %
27.74%
Holding
3,121
New
186
Increased
817
Reduced
1,825
Closed
148

Top Buys

Rank Stock Value
1
RIVN icon
Rivian
RIVN
+$18.7B
2
AAPL icon
Apple
AAPL
+$5.48B
3
NVDA icon
NVIDIA
NVDA
+$5.33B
4
TSLA icon
Tesla
TSLA
+$4.47B
5
MSFT icon
Microsoft
MSFT
+$2.15B

Top Sells

Rank Stock Value
1
V icon
Visa
V
+$4.26B
2
META icon
Meta Platforms (Facebook)
META
+$3.3B
3
MS icon
Morgan Stanley
MS
+$2.82B
4
GPN icon
Global Payments
GPN
+$2.43B
5
PYPL icon
PayPal
PYPL
+$2B

Sector Composition

Rank Sector Weight
1 Technology 27.36%
2 Healthcare 16.09%
3 Consumer Discretionary 15.79%
4 Communication Services 12.38%
5 Financials 10.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BOAC.WS
2926
DELISTED
Bluescape Opportunities Acquisition Corp. Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
BOAC.WS
$39K ﹤0.01%
46,500
HOFV
2927
DELISTED
Hall of Fame Resort & Entertainment Co
HOFV
$37K ﹤0.01%
1,098
-59
-5% -$2.79K
LPTH icon
2928
Lightpath Technologies
LPTH
$862M
$37K ﹤0.01%
15,300
XERS icon
2929
Xeris Biopharma Holdings
XERS
$1.55B
$37K ﹤0.01%
12,700
-51,700
-80% -$112K
IDEX
2930
DELISTED
Ideanomics, Inc. Common Stock
IDEX
$37K ﹤0.01%
247
-37
-13% -$7.9K
HGEN
2931
DELISTED
HUMANIGEN, INC.
HGEN
$37K ﹤0.01%
10,069
-552
-5% -$3.23K
AQMS icon
2932
Aqua Metals
AQMS
$9.56M
$36K ﹤0.01%
147
-162
-52% -$57.1K
OGEN icon
2933
Oragenics
OGEN
$2.42M
$36K ﹤0.01%
44
ZOM
2934
DELISTED
Zomedica Corp.
ZOM
$36K ﹤0.01%
116,100
-390,400
-77% -$176K
POL
2935
DELISTED
Polished.com Inc.
POL
$35K ﹤0.01%
290
EMAN
2936
DELISTED
eMagin Corporation
EMAN
$35K ﹤0.01%
27,300
CLSD
2937
DELISTED
Clearside Biomedical
CLSD
$33K ﹤0.01%
+793
New +$51.4K
TUSK icon
2938
Mammoth Energy Services
TUSK
$158M
$33K ﹤0.01%
18,000
-21,800
-55% -$56.9K
LGMK
2939
DELISTED
LogicMark
LGMK
$32K ﹤0.01%
21
DFTX
2940
Definium Therapeutics
DFTX
$5.75B
$32K ﹤0.01%
1,532
-387
-20% -$12.4K
INUV icon
2941
Inuvo
INUV
$14.2M
$30K ﹤0.01%
5,660
HAACW
2942
DELISTED
Health Assurance Acquisition Corp. Warrants
HAACW
$30K ﹤0.01%
35,000
CLRB icon
2943
Cellectar Biosciences
CLRB
$20.8M
$28K ﹤0.01%
139
CTXR icon
2944
Citius Pharmaceuticals
CTXR
$21M
$27K ﹤0.01%
704
-80
-10% -$3.63K
CATX icon
2945
Perspective Therapeutics
CATX
$372M
$24K ﹤0.01%
6,150
VSTM icon
2946
Verastem
VSTM
$629M
$23K ﹤0.01%
952
-241
-20% -$7.61K
RESN
2947
DELISTED
Resonant Inc.
RESN
$23K ﹤0.01%
13,400
SVRA icon
2948
Savara
SVRA
$1.17B
$21K ﹤0.01%
17,260
AGRX
2949
DELISTED
Agile Therapeutics
AGRX
$21K ﹤0.01%
21
YARW
2950
Yarrow Bioscience, Inc. Common Stock
YARW
$114M
$20K ﹤0.01%
21

Similar funds

T. Rowe Price Associates's Q4 2021 Portfolio in Review

As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.

T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.

By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
  • T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
  • T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
  • T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
  • T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
  • T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
  • T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.

Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.